drugset / Trial / NCT01019668

Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy

NCT01019668

Completed 24 enrolled Shin Kong Wu Ho-Su Memorial Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness as well as the detrimental influence of half-dose and half-fluence modification of verteporfin photodynamic therapy (PDT) for the treatment of prolonged unresolved central serous chorioretinopathy (CSCR).

Timeline

Start
2008-11
Primary completion
2009-12
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Verteporfin Other / unclassified 3 mg/m2 Other
Comparator Verteporfin Other / unclassified 6 mg/m2 Other